SecBot SecBot
Biotech Drug Report Generated Sep 13, 2026

STAR-001

LTRN·Lantern Pharma Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 1 (IND cleared, trial not yet initiated)
Time to market
Unknown, Phase 1 trial has not started; typical development timeline for a rare pediatric cancer drug from Phase 1 to approval is 5-10+ years, if successful.
Why 3/10
STAR-001 has no scheduled binary catalyst in the next ~12 months. The IND was cleared in March 2026, but Phase 1 trial initiation and initial data are likely well over a year away. The drug is one of several pipeline assets at a company with a ~$34M market cap, and more advanced programs (LP-300, LP-184) are the primary value drivers. Per the rubric, an early-stage drug with no near-term dated catalyst scores 3.
Actionable Insight NEUTRAL

STAR-001 has no scheduled near-term binary catalyst, the IND was cleared in March 2026 but Phase 1 trial enrollment and initial data are likely 12+ months away. The stock is more driven by LP-300 HARMONIC trial data, LP-184 regulatory progress, and the company's cash runway (only through mid-Q1 2027). Monitor for Phase 1 trial initiation announcements and any partnership/licensing deals that could fund development.

Price Chart

Loading chart...

Executive Summary

STAR-001 is an early-stage investigational drug from Lantern Pharma Inc. (Nasdaq: LTRN) being developed for pediatric central nervous system (CNS) cancers, specifically Atypical Teratoid Rhabdoid Tumor (ATRT) and other rare pediatric cancers. On March 30, 2026, the FDA cleared Lantern Pharma's Investigational New Drug (IND) application, allowing the company to proceed with a planned Phase 1 clinical trial. The IND clearance was a positive catalyst, driving the stock up ~22% in one day and ~45% in five days. However, STAR-001 remains in the earliest clinical stage with no disclosed trial start date or data readout timeline. Lantern Pharma has a market cap of roughly $34M, cash runway only through mid-Q1 2027, and multiple other pipeline assets (LP-300, LP-184, LP-284) that are more advanced. STAR-001 is a small part of a broader pipeline with no near-term binary catalyst, making it a low-impact program for investors at this stage.

How It Works

STAR-001 is an investigational drug being developed for rare pediatric brain cancers. Its precise mechanism of action is not publicly detailed, but it is being developed under Lantern Pharma's Starlight pediatric oncology program, which leverages the company's RADR AI platform to identify drug candidates for genomically defined cancers. The drug targets Atypical Teratoid Rhabdoid Tumor (ATRT), a rare and aggressive pediatric CNS tumor driven by SMARCB1 gene mutations.

Trial Status

FDA cleared the IND on March 30, 2026, for a planned Phase 1 pediatric CNS cancer trial in ATRT and other rare pediatric cancers. The trial has not yet been initiated or posted on ClinicalTrials.gov as of available data.

The Two-Sided Case

▲ Bull Case5
FDA IND clearance on March 30, 2026, was a positive regulatory milestone that de-risked the program and allowed the Phase 1 trial to proceed, stock reacted with +22% one-day and +45% five-day gains.
ATRT is a rare, aggressive pediatric cancer with no approved targeted therapies, representing a high unmet medical need and potential for expedited regulatory pathways (rare pediatric disease designation, priority review voucher).
Lantern Pharma's RADR AI platform may enable efficient patient selection and biomarker-driven development, potentially improving trial success probabilities.
Analyst consensus is bullish: 7 Buy/Strong Buy ratings vs. 1 Hold, with a mean price target of $17.50 (vs. current ~$1.71), implying massive upside if pipeline succeeds.
Institutional accumulation in Q2 2026: Renaissance Technologies doubled its position (+151%), Vanguard added (+28%), and UBS added (+65%).
▼ Bear Case6
STAR-001 is at the earliest clinical stage (Phase 1 not yet initiated), most oncology drugs fail in Phase 1/2, and pediatric CNS cancer trials face additional enrollment challenges.
Lantern Pharma had only $7.4M in cash as of June 30, 2026, with runway only through mid-Q1 2027, the company will likely need to raise capital, causing dilution, before STAR-001 generates any data.
The company has no approved products or revenue; it is a pre-commercial biotech entirely dependent on pipeline success and external financing.
STAR-001 is a minor program in a pipeline where LP-300 (Phase 2 HARMONIC trial) and LP-184 (Phase 1b/2) are more advanced and likely absorbing most R&D resources.
A dilutive overhang exists from ~2.24M shares registered for resale via warrant exercises (May 2026 offering), which could cap upside.
BlackRock and Dimensional Fund Advisors both trimmed their LTRN positions by >50% in Q2 2026.

Upcoming Catalysts

  • Phase 1 trial initiation announcement (no date disclosed)
  • Initial safety/tolerability data from Phase 1 (likely 12+ months away)
  • Potential partnership or licensing deal for STAR-001 or Starlight program

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Lantern Pharma Inc. 8-K LTRN ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov